Fairmount Funds Management LLC Portfolio Holdings

Fairmount Funds Management LLC

  • $615 Million
  • Q3 2024

Fairmount Funds Management LLC has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $615 Million distributed in 15 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Axsome Therapeutics, Inc. with a value of $212M, Nuvalent, Inc. with a value of $173M, Viridian Therapeutics, Inc.\De with a value of $78.4M, Cogent Biosciences, Inc. with a value of $67.2M, and Day One Biopharmaceuticals, Inc. with a value of $43.2M.

Examining the 13F form we can see an increase of $112M in the current position value, from $504M to 615M.

Fairmount Funds Management LLC is based out at Philadelphia, PA

Below you can find more details about Fairmount Funds Management LLC portfolio as well as his latest detailed transactions.

Portfolio value $615 Million
Healthcare: $615 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$4.06B
$212 Million 34.46% of portfolio
2,360,077
Q4 2023 Added 0.8%
$3.92B
$173 Million 28.04% of portfolio
1,687,064
Q3 2024 Reduced 12.34%
$789M
$78.4 Million 12.74% of portfolio
3,445,813
Q3 2024 Added 86.68%
$597M
$67.2 Million 10.93% of portfolio
6,225,641
Q2 2024 Added 31.74%
$1B
$43.2 Million 7.02% of portfolio
3,103,448
Q3 2024 New
$141M
$39.1 Million 6.36% of portfolio
3,554,129
Q4 2023 Added 86.92%
$604M
$2.8 Million 0.46% of portfolio
123,538
Q3 2024 Reduced 88.45%
Spyre Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2024 Added 961.81%
Oruka Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Apogee Therapeutics Inc
-
$0 0.0% of portfolio
-
Q1 2024 Reduced 30.35%
Kiniksa Pharmaceuticals Intl
-
$0 0.0% of portfolio
-
Q2 2024 New
Enliven Therapeutics Inc
-
$0 0.0% of portfolio
-
Q1 2024 Added 50.27%
Dianthus Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 2.25%
Bicara Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Zenas Biopharma Inc
-
$0 0.0% of portfolio
-
Q3 2024 New

Summary

  • Portfolio
  • No. of Stocks 15
  • Current Value $615 Million
  • Prior Value $504 Million
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 4 stocks
  • Additional Purchases 1 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 3 stocks
Track This Portfolio

Track Fairmount Funds Management LLC Portfolio

Follow Fairmount Funds Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fairmount Funds Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email